Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection

Na-Ri LEE; Ji-Won JANG; Hee-Sun KIM; Ho-Young YHIM.
The Korean Journal of Internal Medicine ; : 550-553, 2015.
Artículo en Inglés | WPRIM | ID: wpr-58257

Documentos relacionados

  1. Correlation Between N-Demethyl Imatinib Trough Concentration and Serious Adverse Reactions in Patients with Gastrointestinal Stromal Tumors: A Retrospective Cohort Study.
  2. [IMATINIB INDUCED EDEMA].
  3. Hyperpigmentation due to imatinib: A rare case of cutaneous involvement.
  4. Sunitinib therapy for imatinib-resistant and/or intolerant gastrointestinal stromal tumors: comparison of safety and efficacy between standard and reduced dosage regimens.
  5. Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib.
  6. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
  7. Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study.
  8. Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients.
  9. 9.4 T static magnetic field ameliorates imatinib mesylate-induced toxicity and depression in mice.
  10. Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST.